First Human Receives Experimental Vaccine Against Rare Ebola Strain
Researchers at the University of Oxford have launched the first human clinical trial for a vaccine targeting the Bundibugyo strain of Ebola. This experimental vaccine aims to fill a critical gap in preparedness, as no licensed treatment currently exists for this specific, deadly strain.
Why it matters
Developing a vaccine for the Bundibugyo strain is a significant step toward improving global health security and preventing future outbreaks in regions where this virus is endemic.
Researchers at the University of Oxford have administered the first dose of an experimental vaccine designed to protect against the Bundibugyo strain of Ebola, marking the world’s first human trial for a vaccine targeting this rare but deadly virus. The Phase I clinical trial, named BD-Ebov, will enroll 50 healthy adults aged 18 to 55 to evaluate the vaccine’s safety and its ability to trigger an immune response.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in